Collegium announced that the FDA has approved oxycodone (Xtampza ER) extended-release capsules, a twice-daily medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The drug uses Collegium’s proprietary DETERx abuse-deterrent technology platform, and is designed to provide adequate pain control while maintaining its drug release profile after being subjected to common